Supplementary material

Polysulfones: solid organic catalysts for the chemoselective cleavage of methyl-substituted allyl ethers under neutral conditions. New strategy for alcohol protection/deprotection.

Dean Marković, Peter Steunenberg, Martin Ekstrand and Pierre Vogel*

Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology, EPFL-BCH CH-1015 Lausanne (Switzerland)

Pierre.Vogel@epfl.ch

General remarks

Commercial reagents (Fluka, Aldrich) were used without purification. Solvents were distilled prior to use: THF from Na and benzophenone. Sulfur dioxide was dried by passing through a column filled with P₂O₅, Al₂O₃ for drying (Fluka 06400), Al₂O₃ basic activated Type 5016A Brockman I (Aldrich 19,944-3). Light petroleum ether used refers to the fraction boiling at 40-60°C. Solutions after reactions and extractions were evaporated in a rotatory evaporator under reduced pressure. Liquid/solid flash chromatography (FC): columns of silica gel (0.040-0.63 mm, Merck No.9385 silica gel 60, 240-400 mesh). TLC for reaction monitoring: Merck silica gel 60F₂₅₄ plates; detection by UV light; Pancaldi reagent [(NH₄)₆MoO₄, Ce(SO₄)₂, H₂SO₄, H₂O] or KMnO₄. IR spectra: Perkin-Elmer-1420 spectrometer. ¹H NMR spectra : Bruker-ARX-400 spectrometer (400 MHz); δ (H) in ppm relative to the solvent's residual ¹H signal [CHCl₃, δ (H) 7.27] as internal reference; all ¹H assignments were confirmed by 2D-COSY-45 spectra. ¹³C NMR spectra : same instrument as above (100.6 MHz); δ (C) in ppm relative to solvent C-signal [CDCl₃, δ (C) 77.0] as internal reference; coupling constants *J* in Hz. MS: Nermag R-10-10C, chemical ionization (NH₃) mode *m/z* (amu) [% relative base peak (100%)], HRMS : Jeol AX-505. Elemental analyses : Ilse Beetz, D-96301 Kronach, Germany.

Poly(methylidenecyclopentane-sulfone) (2)¹



Methylidenecyclopentane (1) was purified by distillation. SO₂ (1.6 ml, 0.0358 mol) was transferred to frozen methylidenecyclopentane (1) (1.0 g, 12.2 mmol) on the vacuum line. Mixture was allowed to warm to -20 °C. After 2 hours, at this temperature, the excess of SO₂, non-reacted methylidenecyclopentene (1) and 1-methylcyclopentene were evaporated under reduced pressure (0.001 Torr). Poly(methylidenecyclopentane-sulfone) (**PS**) (1.3 g, 75 %) was, powdered and neutralized with aqueous solution of NaOH (0.1 N) till pH=7 and washed 3 times by turns with water and CH₂Cl₂. Neutralized polymer was dried on the vacuum line overnight.

For characterization see:

¹D. Marković, P. Vogel, Angew. Chem. Int. Ed. 2004, 43, 2928-2930.

General procedure for deprotection of a allyl ethers

In two necked flask was added allyl ether (0.1 mmol), neutralized poly(methylidenecyclopentane-sulfone) (2) (10 weight%) and 2ml of cyclohexane. Reaction mixture was refluxed under inert atmosphere and followed by TLC. After reaction was finished the liberated alcohol was purified by flash chromatography.

2-(3-Methylbut-2-en-1-yloxy)-1-phenylethanol (18)



NaH (55% in oil dispersion, 2 g , 45.8 mmol) was added to a stirred solution of 1-phenylethane-1,2-diol (17) (3.16 g, 22.9 mmol) in anhydrous DMF (40 mL) under Ar atmosphere at -40 °C. Reaction mixture was heated to -10 °C and prenyl bromide (3.41 g, 22.9 mmol) was added dropwise. Reaction was followed by TLC ($CH_2Cl_2/Ethyl$ acetate=10/1) and, after finishing, quenched with water, extracted with CH_2Cl_2 , dried over MgSO₄ and purified by flash chromatography ($CH_2Cl_2/Ethyl$ acetate=10/1).

Colorless oil, 74 %

IR (film): 3425, 3061, 3028, 2970, 2911, 1950, 1878, 1813, 1668, 1451, 1377, 1328, 1255, 1197, 1097, 1027, 1005, 905.

MS (CI, NH₃): 206 ([M]; 8), 189 (43), 171 (29), 137 (25), 121 (33), 107 (100), 91 (15).

¹**H** NMR (400 MHz, CDCl₃): 7.43-7.26 (m, 5H, H-C(aromatic)), 5.38 (t, 1H, ³J(H, H)=6.8, H-C(2")), 4.97 (ddd, 1H, ³J(H, H)= 9.3, ³J(H, H)=3.1, ³J(H, H)=2.5, H-C(1)), 4.07 (d, 2H, ³J(H, H)=6.8, H-C(1")), 3.60 (dd, 1H, ²J(H, H)=9.9, ³J(H, H)=3.1, H_a-C(2)), 3.44 (dd, 1H, ²J(H, H)=9.9, ³J(H, H)=9.3, H_b-C(2)), 3.00 (d, 1H, ³J(H, H)= 2.5, H-O)), 1.77 and 1.69 (2×s, 2×3H, 2×H-C(4")).

¹³C NMR (100.6 MHz, CDCl₃): 140.3 (s, C(3")), 137.6 (s, C(1")), 128.4 (d, ¹J(C,H)=159, C(3")), 127.7 (d, ¹J(C,H)=161, C(4")), 126.1 (d, ¹J(C,H)=156, C(2")), 120.7 (d, ¹J(C,H)=157, C(2")), 75.6 (d, ¹J(C,H)=141, C(1")), 72.8 (t, ¹J(C,H)=145, C(2)), 67.6 (t, ¹J(C,H)=141, C(1)), 25.8 and 18.0 (2×q, ¹J(C,H)=125, 2×C(4")).

HRMS (MALDI): calcd for $C_{13}H_{18}KO_2^+$ 245.0944 [M+K⁺], found 245.0946



Figure S1. ¹H-NMR spectrum of 2-(3-methyl-but-2-en-1-yloxy)-1-phenylethanol (18)

[1-(2-Methylallyloxy)-2-(3-methylbut-2-en-1-yloxy)ethyl]benzene (19)



NaH (55 % in oil dispersion, 0.5 g, 11.4 mmol) was added to a stirred solution of **18** (2.36 g, 11.4 mmol) in anhydrous DMF (20 mL) under Ar atmosphere at 0 °C. Reaction mixture was stirred for 1 h and methallyl bromide (1.85 g, 13.7 mmol, 1.2 eqv.) was added. Reaction was followed by TLC (petroleum ether /ethyl acetate=10/1), quenching with water, extraction with CH_2Cl_2 , dried over MgSO₄ and purifications by flash chromatography (petroleum ether /Ethyl acetate=10/1).

Colorless oil, 96 %

IR (film): 3063, 3029, 2971, 2915, 2858, 1952, 1810, 1771, 1716, 1651, 1454, 1197, 1059, 1027, 905.

MS (CI, NH₃): 261 ([M+1]; 3), 260 ([M]; 4), 189 (10), 161 (100), 141 (8), 123 (27), 105 (47), 91 (11).

¹**H** NMR (400 MHz, CDCl₃): 7.41-7.28 (m, 5H, H-C(aromatic)), 5.35 (t, 1H, ³J(H, H)=7.0, H-C(2")), 5.00 and 4.91 (2×s, 2×1H, H-C(2"')), 4.56 (dd, 1H, ³J(H, H)= 7.7, ³J(H, H)=3.8, H-C(1)), 4.09 and 4.02 (2×dd, 2×1H, ²J(H, H)=11.5, ³J(H, H)=7.0, H-C(1"')), 3.93 and 3.80 (2×d, 2×1H, ²J(H, H)=11.5, H-C(1")), 3.79 (dd, 1H, ²J(H, H)=10.2, ³J(H, H)=7.7, H_a-C(2)), 3.53 (dd, 1H, ³J(H, H)=10.2, ³J(H, H)=3.8, H_b-C(2)), 1.77, 1.75 and 1.66 (3×s, 3×3H, 2×H-C(4")), H-C(4")).

¹³C NMR (100.6 MHz, CDCl₃): 144.8 (s, C(2'')), 137.0 (s, C(1')), 133.4 (s, C(3''')), 128.7 (d, ¹J(C,H)=153, C(3')), 128.2 (d, ¹J(C,H)=160, C(2')), 127.5 (d, ¹J(C,H)=159, C(4')), 121.7 (d, ¹J(C,H)=160, C(3'')), 112.6 (t, ¹J(C,H)=150, C(3'')), 80.8 (d, ¹J(C,H)=143, C(1)), 75.1 (t, ¹J(C,H)=142, C(1''')), 73.1 (t, ¹J(C,H)=140, C(1'')), 68.3 (t, ¹J(C,H)=140, C(2)), 26.1 and 18.4 (2×q, ¹J(C,H)=126, 2×C(4''')), 20.0 (2×q, ¹J(C,H)=126, 2×C(4'')).

HRMS (MALDI): calcd. for C₁₇H₂₄KO₂⁺ 299.1413 [M+K⁺], found 299.1435



Figure S2. ¹H-NMR spectrum of [1-(2-methylallyloxy)-2-(3-methylbut-2-en-1-yloxy)ethyl]benzene (19)

2-(2-Methylallyloxy)-2-phenylethanol (8)



Yellowish oil, 94 %

IR (film): 3426, 2960, 2928, 1718, 1700, 1451, 1374, 1103, 905.

MS (CI, NH₃):192([M]; 6), 161 (10), 121 (49), 105 (100), 91 (55).

¹**H NMR** (400 MHz, CDCl₃/ a drop of D₂O): 7.43-7.26 (m, 5H, H-C(aromatic)), 4.97 (s, 1H, H-C(3')), 4.92 (s, 1H, H-C(3')), 4.49 (dd, 1H, ${}^{3}J(H, H)$ = 8.4, ${}^{3}J(H, H)$ = 3.9, H-C(2)), 3.93 (d, 1H, ${}^{2}J(H, H)$ = 12.3, H_a-C(1'')), 3.78 (d, 1H, ${}^{2}J(H, H)$ = 12.3, H_b-C(1'')), 3.72 (dd, 1H, ${}^{2}J(H, H)$ = 11.8, ${}^{3}J(H, H)$ = 8.4, H_a-C(1)), 3.63 (dd, 1H, ${}^{2}J(H, H)$ = 11.8, ${}^{3}J(H, H)$ = 3.9, H_b-C(1)), 1.77 (s, 3H, H-C(4')).

¹³C NMR (100.6 MHz, CDCl₃): 141.9 (s, C(2")), 138.5 (s, C(1")), 128.6 (d, ¹J(C,H)=159, C(3")), 128.1 (d, ¹J(C,H)=161, C(4")), 127.0 (d, ¹J(C,H)=156, C(2")), 112.5 (t, ¹J(C,H)=157, C(3")), 81.8 (d, ¹J(C,H)=147, C(2)), 72.6 (t, ¹J(C,H)=137, C(1")), 67.4 (t, ¹J(C,H)=145, C(1)), 19.7 (q, ¹J(C,H)=130, C(4")).

HRMS (MALDI): calcd for $C_{18}H_{30}KO_6^+ 231.0787 [M+K^+]$, found 231.0751.



Figure S3. ¹H-NMR spectrum of 2-(2-methylallyloxy)-2-phenylethanol (8).

2-Methyl-4-(3-methylbut-2-en-1-yloxy)butan-2-ol (20)



NaH (55% in oil dispersion, 1g , 22.9 mmol) was added to a stirred solution of 3-methylbutane-1,3-diol (2.39 g, 22.9 mmol) in anhydrous DMF (40 mL) under Ar atmosphere at 0 °C. After stirring for 1 h, prenyl bromide (3.41 g, 22.9 mmol) was added dropwise. Consumption of starting material was confirmed after 12 h by TLC ($CH_2Cl_2/Ethyl$ acetate=10/1). The mixture was quenched with water, extracted with CH_2Cl_2 , dried over MgSO₄ and purified by flash chromatography ($CH_2Cl_2/Ethyl$ acetate=10/1).

Colorless oil, 92 %

IR (film): 3382, 2931 1721, 1466, 1380, 1151, 880, 652.

¹**H** NMR (400 MHz, CDCl₃): δ 5.24 (m, 1H, H-C(2')), 3.85 (d, 2H ²J(H, H)= 7.0 H-C(1')), 3.56 (t, 2H, ³J(H, H)=6.0, H-C(4)), 1.67 (t, 2H, ³J(H, H)=6.0, H-C(3)), 1.65 and 1.58 (2×s, 2×3H, 2×H-C(4')), 1.14 (s, 6H, C(1)).

¹³C NMR (100.6 MHz, CDCl₃): δ 137.8 (s, C(3')), 121.1 (d, J(C,H)=155, C(2')), 70.9 (s, C(2)), 67.9 (t, J(C,H)=140, C(4)), 67.7(t, J(C,H)=140, C(1')), 41.8 (t, J(C,H)=125, C(3)), 31.3 and 29.7, (2×q, J(C,H)=125, C(1)), 26.5 and 18.0 (2×q, J(C,H)=125, (<u>C</u>H₃)₂C(3')).

MS (CI, NH₃): 155 (2), 139 (54), 123(4), 113 (24), 101 (13, M-C₄H₉O), 85 (100).



Figure S4. ¹H-NMR spectrum of 2-methyl-4-(3-methylbut-2-en-1-yloxy)butan-2-ol (20)

2-Methyl-2(2-methylallyloxy)-4-(3-methyl-but-2-en-1-yloxy)butane (9)



KH (423 mg, 10.5 mmol), washed 5 times with dry pentane and dried on vacuum line, and THF (15 mL) was added in two necked flask under nitogen atmosphere (glove box). Solution of **20** (1.82 g, 10.5 mmol) in anhydrous THF (40 mL) was slowly added for 20 min at 0 °C. After stirring for 1 h at room temperature, in the reaction mixture was added dropwise methallyl bromide (1.7 g, 12.6 mmol, 1.2 eqv.). Reaction mixture was stirred over night and quenched with water, extracted with ether, dried over MgSO₄ and purified by flash chromatography (petroleum ether /Ethyl acetate=10/1).

Colorless oil, 87 %

IR (film): 3074, 2971, 2930, 2858, 1652, 1448, 1378, 1364, 1166, 1098, 894.

¹**H** NMR (400 MHz, CDCl₃): 5.24 (tm, 1H, ³*J*(H, H)= 6.8, H-C(2')), 4.97 and 4.82 (2×s, 2×1H, H-C(2'')), 3.93 (d, 2H, ²*J*(H, H))= 7.4, H-C(1')), 3.76 (s, 2H, H-C(1'')), 3.52 (t, 2H, ³*J*(H, H))= 7.4, H-C(4)), 1.83 (t, 2H, ³*J*(H, H)= 7.4, H-C(3)), 1.73, 1.72 and 1.66 (3×s, 3×3H, H-C(4''), 2×H-C(4')), 1.20 (s, 6H, H-C(1)).

¹³C NMR (100.6 MHz, CDCl₃): 143.3 (s, C(3'')), 136.6 (s, C(3')), 121.1 (d, J(C,H)=154, C(2')), 110.7 (t, J(C,H)=151, C(3'')), 73.9 (s, C(2)), 67.3 (t, J(C,H)=141, C(1'')), 66.3 (t, J(C,H)=141, C(4)), 65.4 (t, J(C,H)=138, C(3')), 40.0 (t, J(C,H)=125, C(3)), 26.0, 25.9 and 25.8, (3×q, J(C,H)=125, 2×C(1), C(4')), 19.7 (q, J(C,H)=125, C(4'')), 17.97 (q, J(C,H)=125, C(4')).

MS (CI, NH₃): 226 ([M]; 4), 199 (25), 175 (86), 139 (55), 113 (70), 85 (100).

HRMS (MALDI): calcd. for C₁₄H₂₆KO₂: 265.1570, found 265.1534.



3-Methyl-3-(2-methylallyloxy)butan-1-ol (10)



Colorless oil, 86 %

IR (film): 3445, 2922, 2852, 1457, 1376, 1145, 1100, 898.

¹**H** NMR (400 MHz, CDCl₃): 4.96 and 4.91 (2×s, 2×1H, H-C(3')), 3.90 (s, 2H, H-C(1')), 3.67 (t, 2H, ³J(H, H))= 5.7, H-C(1)) 3.76 (s, 2H, H-C(1'')), 3.30 (s, 1H, H-O), 1.80 (t, 2H, ³J(H, H)= 5.7, H-C(2)), 1.75 (s, 3H, H-C(4')), 1.26 (s, 6H, H-C(4)).

¹³C NMR (100.6 MHz, CDCl₃): 142.0 (s, C(2')), 121.1 (d, ²J(C,H)=150, C(2')), 110.7 (t, ²J(C,H)= 151, C(3')), 75.7 (s, C(3)), 70.9 (t, J(C,H)=153, C(1')), 68.0 (t, J(C,H)=156, C(1)), 41.8 (t, J(C,H)=129, C(2)), 30.1, 29.8 and 19.8, $(3 \times q, {}^{2}J(C,H)= 125, 2 \times C(4), C(4'))$.

MS (CI, NH₃): 159 ([M+1]; 15), 142 (25), 123 (45), 111 (60), 95 (100), 83 (91).

HRMS (MALDI): calcd. for C₁₄H₂₆KO₂: 197.0944, found 197.0987.



Figure S6. ¹H-NMR spectrum 3-methyl-3-(2-methylallyloxy)butan-1-ol (10)

2-O-Prenyl-β-D-ribo-2,4-anhydro-3-deoxyhexopyranose (22c).

A mixture of isolevoglucosenone **21** (150 mg, 1.0 mmol), prenyl alcohol (300 mg, 2.3 mmol) and triethylamine (14 μ L, 0.10 mmol) was stirred at 20°C for 2h. Excess of alcohol was then eliminated by evaporation in vacuo. The residue was chromatographed on silicagel (1:9 EtOAc/petroleum ether) affording a colorless syrup, which was dissolved in THF (5 mL), cooled to -78 °C. Successively the ketone was reduced by K-selectride (1 M, 1mL). The reaction mixture was allowed to warm to r.t. and stirred overnight. Then methanol and NH₄Cl were added, after stirring for 1h, the reaction mixture was filtrated over Celite and concentrated. The crude was purified by column chromatography (silica, PE:EtOAc 1:1) to obtain **22c** in a yield of 75% (150 mg, 0.7 mmol)



Colorless oil. 75 (%)

 $[\alpha]^{25}_{589}$ -7.7, $[\alpha]^{25}_{577}$ -5.7, $[\alpha]^{25}_{546}$ -9.0 $[\alpha]^{25}_{435}$ -18.7 $[\alpha]^{25}_{405}$ -25.2 (C = 2.0, CHCl₃)

IR (film): 2971, 2864, 1438, 1140, 924, 638, 754

¹**H NMR** (400 MHz, CDCl₃): δ 5.41 (s, 1H, H-C(1)), 5.38 (m, 1H, H-C(2')), 4.48 (s, 1H, H-C(4)), 4.08 (m, 2H, H-C(1a'), H-C(1b')), 3.81 (m, 2H, Ha-C(6),Hb-C(6)), 3.57 (s, 1H, H-C(4)), 3.29 (s, 1H, H-C(2)), 1.91(m, 2H, Ha-C(3), Hb-C(3)), 1.70, 1.67 (2s, 6H, (C<u>H</u>₃)₂-C(3'))

¹³C NMR (100.6 MHz, CDCl₃): δ 137.7 (s, C-(3')), 127.4 (s, C-(2')), 100.4 (d, ¹*J*(C,H)= 175, C-(1)) 77.4 (d, ¹*J*(C;H)= 150 C-(5)), 73.8 (d, ¹*J*(C,H)= 145, C-(4)), 69.9 (d, ¹*J*(C,H)= 140, C-(2)) 65.4 (t, ¹*J*(C;H)= 145, C-(6)), 65.0 (t, ¹*J*(C;H)= 133, C-(1')), 29.6 (1 t, ¹*J*(C,H) 130, C-(3)), 25.8, 25.7 16.6 (3 q, ¹*J*(C,H)= 125, (<u>C</u>H₃)₂C(3'))

MS (CI, NH₃): 233 ([M+18], 99), 232 (100), 215 (36), 164 (99), 130 (99), 112 (31), 81 (71)

HRMS (MALDI): Calcd. for C₁₁H₁₈O₄Na: 237.1103 [M+Na⁺], found: 237.1112





Figure S7. ¹H-NMR spectrum of 2-*O*-prenyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (**22c**)

2-O-Methylprenyl-β-D-ribo-2,4-anhydro-3-deoxy-hexopyranose (22d).

Same procedure as for the preparation of 22c, using 2-methylprenylalcohol instead of prenylalcohol.



Colorless oil. (80%)

 $[\alpha]^{25}_{589}$ - 100.5, $[\alpha]^{25}_{577}$ - 106.7, $[\alpha]^{25}_{546}$ - 109.0 $[\alpha]^{25}_{435}$ - 107.8 $[\alpha]^{25}_{405}$ - 108.2 (C = 2.0, CHCl₃)

IR (film): 3562, 2901, 1190, 1008, 924, 782

¹**H** NMR (400, MHz, CDCl₃): δ 5.40 (d 1H, ³*J*(H-C(1),H-C(2)= 2.5, H-1), 4.50 (m, 1H, H-C(5)), 4.05 (dd, 2H, ²*J*(Ha-C(1'),Hb-C(1')= 10.8, Ha-C(1'), Hb-C(2')), 3.77 (m, 2H,Ha-C(6), Hb-C(6)), 3.56 (m, 1H, H-4), 3.30 (m,1H, H-C(2)), 190, (m, 2H, H-C(3) and H-C(3')), 1.70-1.63 (m, 9H, C(2')-C<u>H₃</u>, C(2')-(C<u>H₃</u>)₂)

¹³C NMR (100.6 MHz, CDCl₃): δ 130.7 (s, C3'), 125.0 (s, C(2')), 100.5 (d, ¹*J*(C,H)= 175, C-(1)), 77.4 (d, ¹*J*(C;H)= 150 C-(5)), 72.8 (1t, ¹*J*(C,H)= 150, C-(4)), 69.9, (t, ¹*J*(C,H)= 125 C-(6)), 67.0 (d, ¹*J*(C;H)= 150, C(2)), 65.4 (t, ¹*J*(C;H)= 133, C-(1')), 27.6 (1 t, ¹*J*(C,H) 130, C-(3)), 20.8, 20.1 16.6 (3 q, ¹*J*(C,H)= 125, (<u>C</u>H₃)₂C(3'))

MS (CI, NH₃): 232 ([M+18], 5), 214 ([M], 5), 234 (7), 145 (65), 99 (63), 83 (100)

HMRS (MALDI): calcd. for C₁₂H₂₀O₄Na: 251.1259, [M+Na⁺] found: 251.1248



Figure S8. ¹H-NMR spectrum of 2-O-methylprenyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (22d)

4-O-Methallyl-2-O-(2-methylprenyl)-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (26d)

To a solution of **22d** (150 mg, 0.6 mmol) in THF at 0 °C was added NaH (40 mg, 1 mmol) and stirred at this temperature for 1h. Afterwards methallyl bromide (0.2 mL, 0.8 mmol) was added and the reaction mixture was allowed to warm to r.t.. The reaction mixture was then heated under reflux until the reaction was completed, quenched by water and extracted with CHCl₂, dried and concentrated. The crude was purified by column chromatography (silica PE:EtOAc 1:4) to obtain **26d** in 68% (130 mg, 0.6 mmol)



Colorless oil. (quantitative)

 $[\alpha]^{25}_{589}$ - 56.9, $[\alpha]^{25}_{577}$ - 65.7, $[\alpha]^{25}_{546}$ - 85.0 $[\alpha]^{25}_{435}$ - 89.7 $[\alpha]^{25}_{405}$ - 86.3 (C = 2.0, CHCl₃)

IR (film): 2925, 2811, 1453, 1376, 1106, 906, 705

¹**H** NMR (400 MHz, CDCl₃): δ 5.46 (s, 1H,H-C(1)), 4.99, 4.91(2 d, 1H ³*J*(H-C(1')-H-C(2'))= 6.8, H-C(2')), 4.61 (d, 1H, ³*J*(H-C-(5)-Ha-C(6)) = 5.6, H-C(5)), 4.01 (m, 2H, Ha-C(2'),Hb-C(2')), 3.75 (m, 1H, Ha-C(6)), 3.73 (dd,1H, ²*J*(Ha-C(6),Hb-C(6))= 8.4, Hb-6), 3.28 (m, 2 H, H-C(2) and H-C(4)), 1.87 (s, 2H, Ha-(3) and Hb-(3)), 1.70, 1.63 (2 s, 6H, C(3')-(C<u>H</u>₃)₂, C(3'')-C<u>H</u>₃))

¹³C NMR (100.6 MHz, CDCl₃): δ 142.2 (s, C-(2')), 129.8 (s, C-(2')), 121.5 (s, C-(3')), 112.3 (t, ¹*J*(C,H)= 135, C(3'')), 101.2 (d, ¹*J*(C,H)= 175, C-(1)), 74.4 (d, ¹*J*(C;H)= 150 C(5)), 72.5 (t, ¹*J*(C,H)= 150, C-(6)), 71.9, 70.9,(2d, ¹*J*(C;H)= 150, C-(2), C-(4)), 69.4 (t, ¹*J*(C;H)= 133, C(-1')), 65.4 (t, ¹*J*(C;H)= 133, C-1''), 24.7 (t, ¹*J*(C,H) 130, C-(3)), 24.2, 19.7, 18.4 (3 q, ¹*J*(C,H)= 125, <u>C</u>H₃C(2''),(<u>C</u>H₃)₂C(3'))

MS (CI, NH₃): 300 ([M+18], 2), 282 ([M], 2), 239 (7), 134 (55), 98 (61), 83 (100)

HMRS (MALDI): calcd. for C₁₂H₂₆KO₄: 305.1729, [M+K⁺] found: 305.1734



Figure S9. ¹H-NMR spectrum of 4-*O*-methallyl-2-*O*-(2-methylprenyl)- β -D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (**26d**)

4-O-Allyl-2-O-(2-methylprenyl)-β-D-ribo-2,4-anhydro-3-deoxyhexopyranose (25d)

Same procedure as for the preparation of 26d, using allyl bromide instead of methallyl bromide.



Colorless oil. (78%)

 $[\alpha]^{25}_{589}$ -75.7, $[\alpha]^{25}_{577}$ -65.8, $[\alpha]^{25}_{546}$ -78.0 $[\alpha]^{25}_{435}$ -107.7 $[\alpha]^{25}_{405}$ -76.2 (C = 2.9, CHCl₃)

IR (film): 2925, 2904, 1455, 1376, 1120, 906, 786

¹**H** NMR (400 MHz, CDCl₃): δ 5.90 (m, 1H, H-C(2'')), 5.41 (s, 1H,H-C(1)), 5.39, (m, 2H, Ha-C(3''), Hb-C(3'')), 4.61 (d, 1H, ²*J*(H-C(4), H-C(5)) = 2.4, H-C(5)), 4.04 (m, 2H, Ha-C(1''), Hb-C(1'')), 3.99 (m, 2H, Ha-C(1'), Hb-C(1')) 3.76 (dd, 1H, ²*J*(Ha-C(6),Hb-C(6)) = 4.8), Ha-C(6)) 3.70 (d, 1H, Hb-C(6), 3.34 (d, 1H,H-C(4)), 3.18 (d, 1H ²*J*(H-C(1),H-C(2) = 2.4), H-C(2)), 1.93, 1.82 (2m, ²*J*(Ha-C(3),Hb-C(3)) = 8.8, Ha-C(3), Hb-C(3)), 172, 1.70, 1.66 (m, 9H, C<u>H</u>₃C(3'), C<u>H</u>₃C(2''))

¹³**C NMR** (100.6 MHzCDCl₃): δ 135.2 (d, ¹*J*(C,H)= 155, C-(2'')), 129.8 (s, C-(2')), 121.9 (s, C-(3')), 121.5 (t, ¹*J*(C,H)= 150,C-(3'')), 101.2 (d, ¹*J*(C,H)= 175, C-(1)), 74.4 (d, ¹*J*(C;H)= 150, C(5)), 72.5, (d, ¹*J*(C,H)= 155, C-(4)), 71.9 (d, ¹*J*(C,H)= 150, C-(2)), 70.9 (t, ¹*J*(C,H)= 140, C-(6)), 65.6, 65.4 (2t, ¹*J*(C;H)= 145, C-(1'), C-(1'')), 29.7 (t, ¹*J*(C,H)= 130, C-(3)), 24.7, 20.8, 16.5 (3 q, ¹*J*(C,H)= 125, <u>C</u>H₃C(2''), (<u>C</u>H₃)₂C(3''))

MS: (CI, NH₃) 286, ([M+18], 8) 278 ([M], 6), 244 (8), 155 (75), 99 (83), 83 (100)

HRMS (MALDI): calcd. for: C₁₅H₂₄NaO₄: 291.1572 [M+Na⁺], found: 291.1512





Figure S10. ¹H-NMR spectrum of 4-*O*-alyll-2-*O*-(2-methylprenyl)-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (**25d**)

4-O-Methallyl-2-O-prenyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (24c)

Same as for the preparation of 22d, using 22c (150 mg, 0.6 mmol) and methallyl bromide (0.2 mL, 0.8 mmol).



Colorless oil. (68%)
$$[\alpha]^{25}_{589}$$
-100.9, $[\alpha]^{25}_{577}$ -106.5, $[\alpha]^{25}_{546}$ -108.0 $[\alpha]^{25}_{435}$ -150.6 $[\alpha]^{25}_{405}$ -187.2 (C = 3.5, CHCl₃)

IR (film): 2925, 1881, 1771, 1455, 1376, 1206, 906

¹**H NMR** (400MHz, CDCl₃): δ 5.58 (s, 1H,H-C(1)) 5.48 (m, 1H, H-C(2')), 5.11, 4.99 (2 s, 2 H, Ha-C(3'') and Hb-C(3'')) 4.74 (m, 1H, H-C(5)), 4.21 (m, 2H, Ha-C(1'') and Hb-C(1'')), 4.13 (m, 2H, Ha-C(1') and Hb-C(1')), 3.90 (m, 1H, ²*J*(Ha-C(6), Hb-C(6))= 8.4, Ha-C(6)), 3.86 (d,1H, Hb-(6)), 3.40 (m, 2H, H-(4) and H-(2)), 2.10, 1.99 (2m, 2H, Ha-(3) and Hb-(3)), 1.89, 1.86, 170 (3 s, 9H, C<u>H</u>₃C(2''),(C<u>H</u>₃)₂C(3'))

¹³C NMR (100.6 MHz, CDCl₃): δ 142.7 (s, C-(2'')), 122.9 (s, C-(3'')), 121.9 (d, ¹*J*(C,H) 150,C-(2'), 112.8 (t, ¹*J*(C,H)= 135, C-(3'')), 101.4 (d, ¹*J*(C,H)= 175, C-(1)), 74.9 (d, ¹*J*(C,H)= 150, C-(5)), 72.9, 72.3, 72.1, (2d, 1t, ¹*J*(C,H)= 150 C-(2), C-(4), C-(6)) 66.1 (t, ¹*J*(C,H)= 133, C-(1')), 65.9 (t, ¹*J*(C,H)= 133, C-(1'')), 26.1 (t, ¹*J*(C,H) 130, C-(3)), 25.2, 19.7, 18.4 (3 q ¹*J*(C,H)= 125, <u>C</u>H₃C(2''), (<u>C</u>H₃)₂C(3'))

MS (CI, NH₃): 286 ([M+18], 10), 273 ([M],15), 235 (10), 155 (65), 100 (65), 83 (100)

HRMS (MALDI): calcd. for C₁₅H₂₄NaO₄: 291.1572, [M+Na⁺] found: 291.1512



Figure S11. ¹H-NMR spectrum of 4-*O*-methallyl-2-*O*-prenyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (24c)

4-O-Allyl-2-O-prenyl-β-D-ribo-2,4-anhydro-3-deoxyhexopyranose (23c)

Same procedure as the preparation of 26d, using 22c and allyl bromide.



Colorless oil. (quantitative).

 $[\alpha]^{25}_{589}$ -105.8, $[\alpha]^{25}_{577}$ -110.7, $[\alpha]^{25}_{546}$ -108.0 $[\alpha]^{25}_{435}$ -170.1 $[\alpha]^{25}_{405}$ -190.2 (C = 3.0, CHCl₃)

IR (film): 2915, 2899, 1455, 1376, 1206, 906

¹**H NMR** (400 MHz, CDCl₃): δ 6.11 (m, 1H, H-C(2'')), 5.58 (s, 1H, H-C(1)), 5.54 (m, 1H, H-C(2')), 5.50 (m, 2H, Ha-C(3'') and Hb-C(3'')) 4.75 (m, 1H, H-C(5)) 4.24 (m, 2H, Ha-C(1'') and Hb-C(1'')) 4.22 (m, 2H, Ha-C(2') and Hb-C(2')), 3.93 (dd, 1H, ²*J*(Ha-C(6), Hb-C(6))= 0 8, Ha-C(6)), 3.86, (d, 1H, Hb-C(6)), 3.47(m, 1H, H-C(4)), 3.41(m, 1H, H-C(2)), 2.11, 2.00 (m, 2H, Ha-(3) and Hb-(3)), 1.86, 1.79 (s, 6H, (C<u>H</u>₃)₂C(3')).

¹³C NMR (100.6 MHz, CDCl₃): 135.7 (s, C-(3')), 125.0 (d, ¹*J*(C,H) 150, C-(2')), 123.9 (s, C-(2'')), 117.0 (t, ¹*J*(C,H)= 135, C-(3'')) 101.2 (d, ¹*J*(C,H)= 175, C-(1)), 74.4 (d, ¹*J*(C,H)= 150, C-(5)), 72.4 (1t, ¹*J*(C,H)= 150, C-(6)), 70.9, 70.5, (2d, 1t, ¹*J*(C,H)= 150 C-(2), C-(4), C-(6)), 69.4(t, ¹*J*(C;H)= 133, C-(1')), 65.4 (t, ¹*J*(C;H)= 133, C-(1'')), 24.5 (t, ¹*J*(C,H) 130, C-(3)), 20.7, 19.7(2 q ¹*J*(C,H)= 125, (CH₃)₂C(3')).

MS (CI, NH₃): 286 ([M+18], 15) 273 ([M], 17), 188 (7), 149 (66), 100 (65), 83 (100).



Figure S12. ¹H-NMR spectrum of 4-*O*-allyl-2-*O*-prenyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (**23c**)

4-O-Allyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (27)

Same procedure as for the preparation of 18, starting with 23c.



Colorless oil.

Starting with 25d: quantitative

Reference: V.A.Zubkov, R.P. Gorshkova, Y.S. Ovodov, A.S. Sviridov, , A.S. Shaskov, Carbohydr. Res., 225, 1992, 189-208.



7.5 7.0 5.5 5.0 4.5 3.5 2.0 1.0 6.5 6.0 2.5

Figure S13. ¹H-NMR spectrum of 4-*O*-allyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (27)

4-O-Methallyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (28)

Same procedure as for 18, starting with 26d.



Colorless oil. (quantitative)

Starting with 24c: 78%

 $[\alpha]^{25}_{589} - 145,5, [\alpha]^{25}_{577} - 156.7, [\alpha]^{25}_{546} - 178.3 \ [\alpha]^{25}_{435} - 190.7 \ [\alpha]^{25}_{405} - 199.2 \ (C = 2.5, CHCl_3)$

IR (film): 3658, 1877, 1465, 1209, 1182, 1058, 805, 765

¹**H** NMR (400 MHz, CDCl₃): δ 5.48 (s, 1H,H-C(1)), 4.97, 4.91 (s, 2 H, Ha-C(3'') and Hb-C(3'')), 4.60 (d, 1H, ³*J*(H-C(5)-H-C(6))= 5.6, H-C(5)), 4.03 (m, 2H, Ha-C(2') and Hb-C(2')), 3.84 (m, 1H, Ha-C(6)), 3.75 (d,1H, ²*J*(Ha-C(6), Hb-C(6)= 8.4, Hb-C(6)), 3.53 and 3.35 (m, 2H, H-C(4) and H-C(2)), 1.98, 1.90, (s, 2H, Ha-C(3) and Hb-C(3)), 1.75 (1 s, 3H, C<u>H</u>₃C(2''))

¹³**C NMR** (100.6 MHz, CDCl₃): δ 142.0 (s, C3''), 113.2 (t, ¹*J*(C,H)= 135, C(3'')), 102.9 (d, ¹*J*(C,H)= 175, C(1)), 77.1 (d, ¹*J*(C;H)= 150, C(5)), 74.5 (1t, ¹*J*(C,H)= 150, C-(6)), 73.8, 73.7(2d, 1t, ¹*J*(C,H)= 150, C-(2), C-(4), C-(6)), 67.9, (t, ¹*J*(C;H)= 133, C-(1')), 65.9 (t, ¹*J*(C;H)= 133, C-(1'')), 28.4 (1 t, ¹*J*(C,H) 130, C-(3)), 19.5, (1q, *J*(C,H)= 125, <u>C</u>H₃C(2''))

MS (CI,NH₃): 234 ([M+18]), 216, ([M], 5), 201 (8), 125 (55), 75 (63), 83 (100)

HRMS (MALDI): calcd. for C₁₀H₁₆NaO₄: 223.0946 [M+Na⁺] found 223.0955



Figure S14. ¹H-NMR-spectrum of 4-*O*-methallyl-β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (28)

β-D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (29)

Same procedure as for 18, starting from 28.



Colorless oil. 75%(%)

Reference: I. Cerny, M. Budesinky, T. Trnka, M, Cerny, Carbohydr. Res., 130, 1984, 103-114.

Supplementary Material (ESI) for Chemical Communications # This journal is © The Royal Society of Chemistry 2004



Figure S15. ¹H-NMR spectrum of β -D-*ribo*-2,4-anhydro-3-deoxyhexopyranose (29)

1,6-Anhydro-3,4-dideoxy-2-*O*-(prenyl)-4-*O*-(trifluoromethanesulfenyl)-β-D-*erythro*-hex-3enopyranose (30/1)

n-Buli (1.6 M in hexane, 0.29 mL, 0.464 mmol) was added dropwise to a solution of $(Me_3Si)_2NH$ (0.10 mL, 0.479 mmol) in 1.5 mL of THF at 0°C. The mixture was stirred at 0°C for 15 min and cooled to -78° C. HMPA (0.080 mL) was aded followed by a solution of isolevoglucosenone **21** (78 mg, 0.236 mmol) in 1.0 mL of THF. Stirring was continued at this temperature for 2h. 2-(*N*,*N*-Bis(trifluoromethylsulfonyl)amino)-5-chloropyridine (157 mg, 0.40 mmol) was then added in one portion. The mixture was stirred for two hours and warmed to 20°C Water (1 mL) was added. The solution was extracted with Et₂O (5mL, 3 times). The combined organic phases were dried (anhydrous Na₂SO₄) and the solvent was removed in vacuo. The residue was purified by flash chromatography on silicagel (3:97) EtOAc/petroleum ether giving a colorless oil (58mg 85%)



Colorless oil. (85%)

 $[\alpha]^{25}_{589}$ -6.8, $[\alpha]^{25}_{577}$ -6.7, $[\alpha]^{25}_{546}$ -8.0 $[\alpha]^{25}_{435}$ -17.7 $[\alpha]^{25}_{405}$ -26.2 (C = 2.9, CHCl₃)

IR (film): 2971, 2963, 1668, 1430, 1218, 1142, 1064, 880, 850

¹**H** NMR (400 MHz, CDCl₃): δ 5.80 (m,1H, H-C(3)), 5.60 (s, 1H, H-C(1)), 5.35 (m, 1H, H-C(3')), 4.77 (d, 1H, ³*J*(H-C(5), Ha-C(6)) = 3.9, H-C(5)), 4.13 (m, 2H, Ha-C(1') and Hb-C(3')), 3.98 (d, 1H, ²*J*(Ha-C(6), Hb-C(6))= 6.7, Ha-C(6)), 3.77 (m, 2H, H-C(4) and Hb-C(6)), 1.71, 1.78 (2s, 6H, (C<u>H_3)</u>₂C(3'))

¹³C NMR (100.6 MHz, CDCl₃): δ 150.6 (s, C-(4)), 138.8 (s, C-(3')), 120.6 (d, ¹*J*(C,H) 150, C-(2')), 113.8 (d, ¹*J*(C;H)=170, C-(3)), 100.8 (d, ¹*J*(C,H)=175, C-(1)), 73.1 (d, ¹*J*(C,H)=150, C(5)), 71.9 (d, ¹*J*(C,H)=150, C-(2)), 69.3 (t, ¹*J*(C,H)=155, C-(6)), 66.5 (t, ¹*J*(C,H)=155, C-(1')), 26.1, 18.2 (2q, ¹*J*(C,H)=125, (<u>C</u>H₃)₂C(3'))

MS (CI, NH₃): 362 ([M+18],7), 344 ([M],15) 236 (9), 201 (75), 99 (62), 85 (100)

HRMS (MALDI): calcd. for $C_{12}H_{15}F_3NaO_6S$: 367.0439 [M+Na⁺] found: 367.0467



Figure S16. ¹H-NMR spectrum of 1,6-anhydro-3,4-dideoxy-2-*O*-(prenyl)-4-*O*-(trifluoromethanesulfenyl)-β-D*erythro*-hex-3-enopyranose (**30**)

1,6-Anhydro-3,4-dideoxy-4-*O*-(trifluoromethanesulfenyl)-β-D-*erythro*-hex-3-enopyranose (31)

Same procedure as for the preparation of 18, starting from $(30/1)^{\wedge}$



Colorless oil. (quantitative)

 $[\alpha]^{25}_{589} - 55.8, \ [\alpha]^{25}_{577} - 56.3, \ [\alpha]^{25}_{546} - 79.8 \ \ [\alpha]^{25}_{435} - 101.3 \ \ [\alpha]^{25}_{405} - 145.2 \ (C = 2.0, CHCl_3)$

IR (film): 3664, 1765, 1355, 1119, 1082, 1043, 791, 749

¹**H NMR** (400 MHz, CDCl₃): δ 5.81 (m,1H, H-C(3)), 5.54 (s, 1H, H-C(1)), 4.75 (d, 1H, ³*J*(H-C(5), Hb-C(6))= 4.3, H-C(5)), 3.99 (m, 1H, H-C(4) and Ha-C(6)), 3.78 (dd, 1H, Hb-C(6))

¹³C NMR (100.6 MHz, CDCl₃): δ 117 (d, ¹*J*(C;H)= 165, C-(3)), 101.9 (d, ¹*J*(C,H)=175), C-(1)), 71.8 (d, ¹*J*(C,H)=150, C-(5)), 68.9 (t, ¹*J*(C,H)= 150 C-(6)), 67.0 (d, ¹*J*(C,H)= 150, C-(2))

MS (CI, NH₃): 293 (M+18,7), 275 (M,15) 255 (10), 175 (75), 97 (77), 81 (100)

HRMS (MALDI): calcd. for C₇H₇KO₆S: 314.9552 [M+K⁺], found 314.9541.



Figure S17. ¹H-NMR spectrum of 1,6-anhydro-3,4-dideoxy-4-*O*-(trifluoromethanesulfenyl)-β-D-*erythro*-hex-3-enopyranose (**31**)